Methods for the treatment of thyroid eye disease
AssigneeHorizon Therapeutics Ireland DAC
InventorsJeffrey W. Sherman, Dennis A. Bennett, Srini Ramanathan, Yan Xin, Elizabeth Thompson, Elizabeth O'Neill
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of treating or reducing the severity of thyroid eye disease (TED), also known as thyroid-associated ophthalmopathy (TAO), or Graves' ophthalmopathy or orbitopathy (GO), as well as antibodies, or antigen binding fragments thereof, and pharmaceutical compositions comprising them, useful in the methods.
Claims19
A method of reducing proptosis in a subject with moderate-to-severe inactive/chronic thyroid eye disease (TED), comprising administering to the subject an effective amount of an insulin-like growth factor-I receptor (IGF-1R) inhibitor, wherein the IGF-1R inhibitor is an antibody that specifically binds to IGF-1R and inhibits the binding of IGF-I and IGF-II to IGF-1R, and wherein the subject with moderate-to-severe inactive/chronic TED has all of the following characteristics:
- (i) an increase of ≥3 mm proptosis relative to the subject's value prior to diagnosis of TED or an increase of ≥3 mm proptosis above the normal values for the subject's race and gender;
- (ii) a clinical activity score (CAS) of 0 or 1 in both eyes as determined by the seven-item scale;
- and
- (iii) no inflammatory symptoms for at least one year prior to administration of the antibody.
A method of reducing proptosis in a subject with moderate-to-severe inactive/chronic TED, comprising administering to the subject teprotumumab, wherein the subject with moderate-to-severe inactive/chronic TED has all of the following characteristics:
- (i) an increase of ≥3 mm proptosis relative to the subject's value prior to diagnosis of TED or an increase of ≥3 mm proptosis above the normal values for the subject's race and gender;
- (ii) a CAS of 0 or 1 in both eyes as determined by the seven-item scale;
- and
- (iii) no inflammatory symptoms for at least one year prior to administration of teprotumumab,
- wherein proptosis is reduced in the subject by at least 2 mm.
Dependencies are inferred from the claim text.